Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$940.00K$940.00K+51.1% vs Q1 2021 Net Income-$5.13M-$5.13MN/M vs Q1 2021 EPS Diluted-$0.23-$0.23N/M vs Q1 2021 Operating Income-$5,164,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,788,000N/M Margins · derivedOperating margin-549.4%+314.3 pt vs Q1 2021
Net margin-545.6%+309.7 pt vs Q1 2021
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end